par Rothé, Françoise 
;Silva, Maria Joao;Venet, David ;Campbell, Christine;Bradburry, Ian;Rouas, Ghizlane;de Azambuja, Evandro ;Maetens, Marion ;Fumagalli, Debora ;Rodrik-Outmezguine, Vanessa;Di Cosimo, Serena;Rosa, Daniela;Chia, Stephen;Wardley, Andrew;Ueno, Takayuki;Janni, Wolfgang;Huober, Jens;Baselga, José;Piccart-Gebhart, Martine ;Loi, Sherene ;Sotiriou, Christos ;Dawson, Sarah Jane;Ignatiadis, Michail
Référence Clinical cancer research, 25, 12, page (3581-3588)
Publication Publié, 2019-06-01
;Silva, Maria Joao;Venet, David ;Campbell, Christine;Bradburry, Ian;Rouas, Ghizlane;de Azambuja, Evandro ;Maetens, Marion ;Fumagalli, Debora ;Rodrik-Outmezguine, Vanessa;Di Cosimo, Serena;Rosa, Daniela;Chia, Stephen;Wardley, Andrew;Ueno, Takayuki;Janni, Wolfgang;Huober, Jens;Baselga, José;Piccart-Gebhart, Martine ;Loi, Sherene ;Sotiriou, Christos ;Dawson, Sarah Jane;Ignatiadis, Michail Référence Clinical cancer research, 25, 12, page (3581-3588)
Publication Publié, 2019-06-01
Article révisé par les pairs
| Résumé : | In the neoadjuvant treatment (NAT) setting, dual HER2-targeted therapy is associated with increased pathologic complete response (pCR) rates compared with each therapy alone. Biomarkers allowing to predict treatment response during NAT are needed. We aim to evaluate whether circulating tumor DNA (ctDNA) is associated with response to anti-HER2-targeted therapy. |
